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Abstract
Background: hyperlipidemia as a major risk factor of atherosclerosis is treated with different
drugs. Concerning length of therapy and vast majority of side effects, herbal medication may be
suitable substitute for these drugs.
Methods: In this single-blind, placebo controlled study, lipid profiles of 150 hyperlipidemic
patients in cardiology outpatient department of Shiraz University of Medical Sciences were
checked at same conditions. They were divided into three equal groups randomly (each
composing of 50 patients). They were given enteric-coated garlic powder tablet (equal to 400
mg garlic, 1 mg allicin) twice daily, anethum tablet (650 mg) twice daily, and placebo tablet. All
patients were put on NCEP type Π diet and Six weeks later, lipid profiles were checked.
Results: In garlic group: total cholesterol (decreased by 26.82 mg/dl, 12.1% reduction, and P-
value: .000), and LDL-cholesterol (decreased by 22.18 mg/dl, 17.3% reduction, and P-value: .000)
dropped. HDL-cholesterol (increased by 10.02 mg/dl, 15.7% increase, and P-value: .000)
increased. Although triglyceride dropped by 13.72 mg/dl (6.3%) but this was not significant
statistically (P-value: .222). In anethum group: surprisingly, triglyceride increased by 14.74 mg/dl
(6.0%). Anethum could reduce total cholesterol by 0.4 % and LDL-cholesterol by 6.3% but these
were not significant statistically (P-value: .828, and .210, respectively).
Conclusion: Anethum has no significant effect on lipid profile, but garlic tablet has significant
favorable effect on cholesterol, LDL-cholesterol, and HDL-cholesterol. Garlic may play an
important role in therapy of hypercholesterolemia.
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Background
Atherosclerosis remains the major cause of death and pre-
mature disability. Hyperlipidemia is the most firmly
established and best understood risk factor for atheroscle-
rosis [1]. Nowadays, major drugs used for treatment of
hyperlipidemia have several adverse effects. Herbal medi-
cations such as Garlic (Allium sativum) and Anethum gra-
veolens are prescribed as antihyperlipidemic agents.
The medicinal uses of garlic have a long history [2]. Recent
studies have validated many of its useful properties, such
as:
• Cancer-preventive actions [3-5]
• Stimulation of phagocytotic function of macrophages
and lymphocyte proliferation [6]
Antimicrobial effects. In vitro, allicin, the main organosul-
fur compound of garlic, has demonstrated activity against
gram-positive and gram-negative bacteria as well as fungi,
protozoa, and certain viruses [7].
• The cardiovascular-protective effects of garlic have been
evaluated extensively in recent years. In animal experi-
ments, garlic extracts have been shown to lower plasma
lipid and cholesterol in rats [[8,9], and [10]], rabbits [11],
chickens [12], and swine [13]. Moreover, a number of
intervention studies have similarly shown that garlic sig-
nificantly reduced plasma lipids, especially total choles-
terol and Low Density Lipoprotein (LDL) cholesterol in
humans [[14,15], and [16]]. Aside from the reported
antiplatelet aggregation and antithrombotic action [17],
garlic reduced blood pressure [[18,19], and [20]] and
stimulated fibrinolytic activity [21,23]. It was reviewed
that aged garlic extract contains antioxidant compounds
and increase nitric oxide production and decreases the
output of inflammatory cytokines from cultured cells.
These data suggest that garlic may improve impaired
endothelial function in men with coronary disease treated
with aspirin and statin [22]. Two meta-analyses of rand-
omized, placebo-controlled human studies confirmed the
hypocholesterolemic effects of garlic [24,25]. The analyses
further detected that the extent of the cholesterol-lowering
properties of garlic differed markedly from one study to
another [24,25]. It was estimated from the five rand-
omized clinical trials that hypercholesterolemic patients
treated with garlic had a mean plasma cholesterol concen-
tration that was 9% lower than that of patients treated
with placebo [25]. Silagy and Neil [25], on the other
hand, concluded from the analysis of 17 human studies
that plasma cholesterol concentrations of the subjects
treated with garlic were 12% lower than those receiving
placebo. Furthermore, the two analyses detected a wide 
range of decrease in mean plasma cholesterol concentra-
tions (i.e., 6–53 mg/dl) among the studies. However, gar-
lic supplementation has been shown not to decrease
plasma cholesterol concentrations in human [[26,27],
and [28]]. Although the reasons for the inconsistent
observations are not readily apparent, it is worthwhile to
note that garlic contains a variety of organosulfur com-
pounds, amino acids, vitamins and minerals [2]. Some of
the sulfur compounds such as allicin, ajoene, S-allyly-
cysteine (SAC), diallyl disulfide (DADS), S-methyl-
cysteine sulfoxide, and S-allylcysteine sulfoxide may be
responsible for the therapeutic properties of garlic [9].
Animal studies have shown that garlic supplementation
in the diet depressed the hepatic activities of lipogenic and
cholesterogenic enzymes such as 3-hydroxy-3-methyl-glu-
taryl-CoA(HMG-CoA) reductase [29].
Anethum graveolens is another herbal medication with
antihyperlipidemic effects. Administration of water
extract of anethum graveolens leaves for 14 days can
reduce triglyceride and total cholesterol levels by almost
50 % and 20 %, respectively [30].
Nowadays, there is wide spread belief among general pub-
lic that garlic and anethum graveolens have beneficial
effects on hyperlipidemia. This belief persuaded us to per-
form this investigation.
Materials and methods
A single-blind, randomized, placebo-controlled interven-
tion study was conducted on patients with coronary artery
disease with newly diagnosed hyperlipidemia. One hun-
dred and seventy two patients were selected from cardiol-
ogy outpatient department of Shiraz University of Medical
Sciences. Exclusion criteria included; having significant
hepatic, renal and gastrointestinal tract disease, acute
myocardial infarction, uncontrolled endocrine disease,
and underlying previous therapies for hyperlipidemia.
Twenty two cases were excluded. One hundred and fifty
patients had total cholesterol level ≥ 200 mg/dl and/or
LDL-cholesterol ≥ 100 mg/dl after 10 hours of fasting with
standard enzymatic methods. Also, we checked HDL-cho-
lesterol and triglyceride. Written informed consent was
obtained from each patient before any study-specific pro-
cedure.
We randomly divided patients into three groups, each
composing of 50 cases. Garlic group received enteric-
coated garlic powder tablet (equal to 400 mg garlic and 1
mg allicin) twice daily. Patients of Anethum group were
prescribed anethum tablet 650 mg twice daily. Placebo
group were given placebo. Demographic information of
different groups is in table 1. After 6 weeks, we checkedLipids in Health and Disease 2007, 6:5 http://www.lipidworld.com/content/6/1/5
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total cholesterol, LDL-cholesterol, HDL-cholesterol, and
triglyceride after 10 hours of fasting.
All patients were given NCEP type Π, i.e. protein about 0.6
g/kg desirable body weight per day, 55 % of total calories
from carbohydrate, no more than 30 % of total energy
intake be derived from dietary fat, polyunsaturated fats to
<10 %, saturated fat & trans-fat should be limited to <10
% of calories, throughout the study.
Data were analyzed by paired sample t  test and non
parameter 2 related sample test using SPSS 13.0 program
for windows (SPSS Inc. Chicago, Illinois). A difference
was considered statistically significant when the probabil-
ity value (P-value) was < 0.05.
Results
Fortunately, all of the patients cooperated well and did
not show any adverse effect of these herbal drugs.
Changes of lipid profiles after 6 weeks and results of
paired t test are shown in table 2 and 3, respectively. It was
found that changes in triglyceride, total cholesterol, LDL-
cholesterol, and HDL-cholesterol were significantly differ-
ent between three groups.
Placebo
Placebo could not improve lipid profile. Triglyceride, total
cholesterol, and LDL-cholesterol increased and HDL-cho-
lesterol was reduced. These changes were not meaningful
(P-value > 0.05).
Anethum graveolens
Anethum didn't have any beneficial effect on triglyceride
(6.0% increase) and HDL-cholesterol (3.1% reduction). It
could reduce total cholesterol by 0.4 % and LDL-choles-
terol by 6.3 %, but these reductions were not significant
statistically (P-value: .828, .210, respectively).
Garlic
At the end of the six-week intervention period, it was fond
that changes in triglyceride, total cholesterol, LDL-choles-
terol, and HDL-cholesterol were significantly different
from other groups. The mean total cholesterol concentra-
tion dropped in the garlic group by 26.82 mg/dl (P-value:
.000.) Similarly, LDL-cholesterol was reduced in this
group by 22.18 mg/dl (P-value: .000). Surprisingly, HDL-
cholesterol was increased by 10.02 mg/dl (P-value: .000).
Although triglyceride dropped by 13.72 mg/dl but this
was not meaningful (P-value: .222).
Discussion
Garlic
Our study suggests that garlic reduces total cholesterol &
LDL-cholesterol. This is similar to Alder and Holub's
study (11.5% decrease of total cholesterol, and 14.2%
decrease of LDL-cholesterol) [31], Tohidi and Rahbani's
trial (9.0% decrease of total cholesterol, 15.0% decrease
of LDL-cholesterol)[32], study of Steiner et al (6.1%
decrease of total cholesterol, 4.0% decrease of LDL-cho-
lesterol) [18]. Also, other studies explained these benefits
[24,25].
HDL-cholesterol should be investigated in more clinical
trials. Stevinson et al [33] in meta-analysis of randomized
clinical trials on antihyperlipidemic effect of garlic
explained that a slight increase in HDL-cholesterol level in
the garlic group was not significantly different from the
effect of placebo. Our search could corroborate garlic
effect on increasing HDL-cholesterol (P-value: .000, HDL-
cholesterol increased by 15.7%)
Triglyceride dropped by prescription of garlic tablet by
6.3% (13.72 mg/dl), according to Tohidi and Rahbani's
study [32], and Mader's trial [34]. But due to P-value:
.222, this reduction was not significant difference from
the effect of placebo.
Anethum graveolens
Anethum could reduce total cholesterol and LDL-choles-
terol (1.12 mg/dl and 9.34 mg/dl, respectively) but these
differences were not significant (P-value: .828 and .210,
respectively). Surprisingly, it reduced HDL-cholesterol
(3.1%) and increased triglyceride level by 6.0%. Our
study on anethum is opposite to that of Yazdanparast and
Alavi [34].
Table 1: Demographic characteristics of different groups
Garlic group Anethum group Placebo group Total
Numbers 50 50 50 150
Female 32 33 30 95
Male 18 17 20 55
Age (year)
Mean 55 55.56 56.5 55.8
Minimum 39 31 39 31
Maximum 78 75 74 78Lipids in Health and Disease 2007, 6:5 http://www.lipidworld.com/content/6/1/5
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Table 3: Results of paired t test in different groups.
mean Standard 
deviation
95% confidence interval of the 
difference
tP - v a l u e
Lower Upper
Garlic
TG1 – TG2 13.72 78.38 -8.56 36.00 1.238 0.222
TC1 – TC2 26.82 33.61 17.27 36.37 5.642 0.000
LDL1–LDL2 22.18 31.91 13.11 31.25 4.915 0.000
HDL1–HDL2 -10.02 10.55 -13.02 -7.02 -6.715 0.000
Anethum
TG1 – TG2 -14.74 73.59 -35.65 6.17 -1.416 0.163
TC1 – TC2 1.12 36.24 -9.18 11.42 0.219 0.828
LDL1–LDL2 9.34 51.96 -5.43 24.11 1.271 0.210
HDL1–HDL2 1.42 10.30 -1.51 4.35 0.975 0.334
Placebo
TG1 – TG2 -4.44 30.66 -13.15 4.27 -1.024 0.311
TC1 – TC2 -4.60 21.76 -10.78 1.58 -1.495 0.141
LDL1–LDL2 -2.30 14.71 -6.48 1.88 -1.106 0.274
HDL1–HDL2 2.14 7.90 -0.10 4.38 1.916 0.061
T C: Total Cholesterol, LDL: Low Density Lipoprotein Cholesterol, HDL: High Density Lipoprotein Cholesterol, TG: Triglyceride
Table 2: Changes in lipid profile after 6 weeks
Garlic Anethum Placebo
Mg/dl percent Mg/dl percent Mg/dl percent
Triglyceride ↓ 13.72 ↓ 6.3 ↑ 14.74 ↑ 6.0 ↑ 4.44 ↑ 2.0
T C ↓ 26.82 ↓ 12.1 ↓ 1.12 ↓ 0.4 ↑ 4.6 ↑ 2.0
LDL ↓ 22.18 ↓ 17.3 ↓ 9.34 ↓ 6.3 ↑ 2.3 ↑ 1.6
HDL ↑ 10.02 ↑ 15.7 ↓ 1.4 ↓ 3.1 ↓ 2.14 ↓ 4.6
T C: Total Cholesterol, LDL: Low Density Lipoprotein Cholesterol, HDL: High Density Lipoprotein CholesterolPublish with BioMed Central    and   every 
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In conclusion we found that enteric-coated garlic tablet
can reduce total cholesterol, LDL-cholesterol and increase
HDL-cholesterol, with no effect on triglyceride. On the
other hand, anethum graveolens can not be an antihyper-
lipidemic agent.
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